MapLight Therapeutics, Inc. announced the topline results from the IRIS (ML-004-002) Phase 2 study of ML-004 in autism spectrum disorder. The company will hold a conference call on June 22, 2026, to discuss these trial results. MapLight Therapeutics, Inc. is a biotechnology company focused on developing therapeutic solutions for neurological and neurodevelopmental disorders.
